Read by QxMD icon Read


Ana S Nunes, Elisabete C Costa, Andreia S Barros, Duarte de Melo-Diogo, Ilídio J Correia
In vitro 3D cancer spheroids generally exhibit a drug resistance profile similar to that found in solid tumors. Due to this property, these models are an appealing for anticancer compounds screening. Nevertheless, the techniques and methods aimed for drug discovery are mostly standardized for cells cultured in 2D. The development of 2D cell culture models displaying a drug resistant profile is required to mimic the in vivo tumors, while the equipment, techniques and methodologies established for conventional 2D cell cultures can continue to be employed in compound screening...
September 22, 2018: Biotechnology Journal
Sibel Cetintas, Gulcin Tezcan, Berrin Tunca, Unal Egeli, Mustafa Sehsuvar Gokgoz, Gulsah Cecener
Distant organ tumor dissemination is a major cause of breast cancer-related deaths. In 2010, we analyzed the prognostic importance of the circulating tumor markers (CTM) cytokeratin (CK)19, CK20, epidermal growth factor receptor (EGFR) and human epidermal growth factor receptor 2 (HER2) in relation to the clinical and pathological characteristics of patients with breast cancer (BC). To assess the clinical utility of CK19, CK20 and EGFR in predicting distant metastasis and recurrence in BC, here we report 7-year follow-up results of 77 patients...
September 17, 2018: Bosnian Journal of Basic Medical Sciences
Soha Talima, Hebatallah Kassem, Neemat Kassem
The online version of the original article can be found.
September 21, 2018: Breast Cancer: the Journal of the Japanese Breast Cancer Society
Chloe Christina Kimball, Christine Ida Nichols, Joshua Greene Vose, Anne Warren Peled
BACKGROUND: Oncoplastic breast surgery aims to optimize efficacy of surgical resection and cosmesis to maximize patient satisfaction; however, despite the benefits, oncoplastic techniques have not been widely adopted in the US. This study examined trends in the incidence of lumpectomy (partial mastectomy) with or without oncoplastic techniques from 2011 to 2016. METHODS: This was a retrospective analysis of claims from the Optum Clinformatics database (January 2010-March 2017)...
September 21, 2018: Annals of Surgical Oncology
April Phantana-Angkool, Meghan R Forster, Yancey E Warren, Chad A Livasy, Amy H Sobel, Lakesha M Beasley, Sally J Trufan, Lejla Hadzikadic-Gusic, Terry Sarantou, Amy E Voci, Deba Sarma, Richard L White
PURPOSE: Radial scars (RS) commonly present mammographically as architectural distortions, but these lesions may be associated with non-invasive and invasive breast cancer. Digital breast tomosynthesis (DBT) has resulted in higher detection rates of architectural distortion particularly in patients with dense breast tissue. We hypothesized that rates of clinically relevant lesions confirmed surgically would be lower in patients who received DBT imaging compared with those who received standard digital breast imaging...
September 21, 2018: Breast Cancer Research and Treatment
Anamika Bhargava, Sumit Saha
PURPOSE: The purpose of this review article is to discuss the potential of T-type voltage gated calcium channels (VGCCs) as drug targets in breast cancer. Breast cancer, attributable to the different molecular subtypes, has a crucial need for therapeutic strategies to counter the mortality rate. VGCCs play an important role in regulating cytosolic free calcium levels which regulate cellular processes like tumorigenesis and cancer progression. In the last decade, T-type VGCCs have been investigated in breast cancer proliferation...
September 21, 2018: Breast Cancer Research and Treatment
Y Shen, T Fujii, N T Ueno, D Tripathy, N Fu, H Zhou, J Ning, L Xiao
BACKGROUND: Trastuzumab (H) with chemotherapy benefits patients with HER2+ breast cancer (BC); however, we lack head-to-head pairwise assessment of survival or cardiotoxicity for specific combinations. We sought to identify optimal combinations. METHODS: We searched PubMed, updated October 2017, using keywords "Breast Neoplasms/drug therapy," "Trastuzumab," and "Clinical Trial" and searched Cochrane Library. Our search included randomized trials of adjuvant H plus chemotherapy for early-stage HER2+ BC, and excluding trials of neoadjuvant therapy or without data to obtain hazard ratios (HRs) for outcomes...
September 21, 2018: Breast Cancer Research and Treatment
Hiroji Iwata, Norikazu Masuda, Yutaka Yamamoto, Tomomi Fujisawa, Tatsuya Toyama, Masahiro Kashiwaba, Shoichiro Ohtani, Naruto Taira, Takehiko Sakai, Yoshie Hasegawa, Rikiya Nakamura, Hiromitsu Akabane, Yukiko Shibahara, Hironobu Sasano, Takuhiro Yamaguchi, Kentaro Sakamaki, Helen Bailey, Diana B Cherbavaz, Debbie M Jakubowski, Naoko Sugiyama, Calvin Chao, Yasuo Ohashi
PURPOSE: The Recurrence Score test is validated to predict benefit of adjuvant chemotherapy. TransNEOS, a translational study of New Primary Endocrine-therapy Origination Study (NEOS), evaluated whether Recurrence Score results can predict clinical response to neoadjuvant letrozole. METHODS: NEOS is a phase 3 clinical trial of hormonal therapy ± adjuvant chemotherapy for postmenopausal patients with ER+, HER2-negative, clinically node-negative breast cancer, after six months of neoadjuvant letrozole and breast surgery...
September 21, 2018: Breast Cancer Research and Treatment
Enoch Chang, Sarah S Mougalian, Kerin B Adelson, Melissa R Young, James B Yu
PURPOSE: The prevalence of patients living with prolonged interval between initial breast cancer diagnosis and development of subsequent metastatic disease may be increasing with improved treatment. In order to counsel these patients as to their prognosis, we investigated the association between metastatic free interval (MFI) and subsequent survival from newly diagnosed metastatic breast cancer (MBC) in a population-level U.S. cohort. METHODS: The Surveillance, Epidemiology and End Results database was used to identify patients with both an initial stage 1-3 breast cancer diagnosis and subsequent MBC diagnosis recorded from 1988 to 2014...
September 21, 2018: Breast Cancer Research and Treatment
Chenglong Wang, Chunjun Liu, Giorgio Giatsidis, Hao Cheng, Lin Chen, Deni Kang, Adriana C Panayi, Jie Luan
BACKGROUND: Three-dimensional (3D) imaging offers new opportunities to enable objective and quantitative analysis of the breast. Unlike scanning of rigid objects, respiration may be one of the factors that can influence the measurement of breast when using 3D imaging. In this study, we aimed to investigate how the different respiratory phases affect 3D morphologic and volumetric evaluations of the breast. METHODS: We performed preoperative 3D breast imaging at the end of expiration (EE) and the end of inspiration (EI)...
September 21, 2018: Aesthetic Plastic Surgery
Dong Sik Bae, Do Hoon Koo
INTRODUCTION: The aim of this study, from a surgical, oncological, and functional perspective, was to identify whether bilateral axillo-breast approach robotic total thyroidectomy (RTT) for differentiated thyroid cancer (DTC) has different surgical outcomes compared to open total thyroidectomy (OTT). METHODS: Initially, 796 patients who underwent total thyroidectomy were primarily reviewed and 178 who were ineligible for analysis were excluded. Propensity score matching analysis adjusted for clinicopathological characteristics (sex, age, body mass index, extent of central node dissection, tumor size, extrathyroidal extension, and thyroiditis) was conducted, with 246 patients in the OTT group matched with 123 patients in the RTT group...
September 21, 2018: World Journal of Surgery
Kara A Michels, Britton Trabert
No abstract text is available yet for this article.
September 13, 2018: JAMA Oncology
Leisha A Emens, Cristina Cruz, Joseph Paul Eder, Fadi Braiteh, Cathie Chung, Sara M Tolaney, Irene Kuter, Rita Nanda, Philippe A Cassier, Jean-Pierre Delord, Michael S Gordon, Ehab ElGabry, Ching-Wei Chang, Indrani Sarkar, William Grossman, Carol O'Hear, Marcella Fassò, Luciana Molinero, Peter Schmid
Importance: Atezolizumab (anti-programmed cell death ligand 1 [PD-L1]) is well tolerated and clinically active in multiple cancer types. Its safety and clinical activity in metastatic triple-negative breast cancer (mTNBC) has not been reported. Objective: To evaluate the safety, clinical activity, and biomarkers associated with the use of single-agent atezolizumab in patients with mTNBC. Design, Setting, and Participants: Women with mTNBC (defined by investigator assessment) were enrolled between January 2013 and February 2016 in a multicohort open-label, phase 1 study at US and European academic medical centers...
September 13, 2018: JAMA Oncology
Ellen C Grant
No abstract text is available yet for this article.
September 13, 2018: JAMA Oncology
Jie Lan, Haiquan Lu, Debangshu Samanta, Shaima Salman, You Lu, Gregg L Semenza
Breast cancer stem cells (BCSCs), which are characterized by a capacity for unlimited self-renewal and for generation of the bulk cancer cell population, play a critical role in cancer relapse and metastasis. Hypoxia is a common feature of the cancer microenvironment that stimulates the specification and maintenance of BCSCs. In this study, we found that hypoxia increased expression of adenosine receptor 2B (A2BR) in human breast cancer cells through the transcriptional activity of hypoxia-inducible factor 1...
September 21, 2018: Proceedings of the National Academy of Sciences of the United States of America
Nadia Saadat, Fangchao Liu, Brittany Haynes, Pratima Nangia-Makker, Xun Bao, Jing Li, Lisa Polin, Smiti Gupta, Guangzhao Mao, Malathy P Shekhar
The triple negative breast cancer (TNBC) subtype regardless of their BRCA1 status has the poorest outcome compared to other breast cancer subtypes and currently there are no approved targeted therapies for TNBC. We have previously demonstrated the importance of Rad6-mediated translesion synthesis pathway in TNBC development/progression and chemoresistance, and the potential therapeutic benefit of targeting Rad6 with a Rad6-selective small molecule inhibitor SMI#9. To overcome SMI#9 solubility limitations, we recently developed a gold nanoparticle (GNP)-based platform for conjugation and intracellular release of SMI#9, and demonstrated its in vitro cytotoxic activity towards TNBC cells...
September 21, 2018: Molecular Cancer Therapeutics
Micaela Montanari, Maria R Carbone, Luigi Coppola, Mario Giuliano, Grazia Arpino, Rossella Lauria, Agostina Nardone, Felicia Leccia, Meghana V Trivedi, Corrado Garbi, Roberto Bianco, Enrico V Avvedimento, Sabino De Placido, Bianca Maria Veneziani
The surface glycoprotein Thy1 is a marker of myoepithelial precursor cells, which are basal cells with epithelial-mesenchymal intermediate phenotype originating from the ectoderm. Myoepithelial precursor cells are lost during progression from in situ to invasive carcinoma. To define the functional role of Thy1-positive cells within the myoepithelial population we tracked Thy1 expression in human breast cancer samples, isolated Thy-positive myoepithelial progenitor cells (CD44+/CD24low/CD90+) and established long term cultures (parental cells)...
September 21, 2018: Molecular Cancer Research: MCR
Yonggeng Goh, Ghayathri Balasundaram, Mohesh Moothanchery, Amalina Attia, Xiuting Li, Hann Qian Lim, Neal Burton, Yi Qiu, Thomas Choudary Putti, Ching Wan Chan, Philip Iau, Siau Wei Tang, Celene Wei Qi Ng, Felicity Jane Pool, Premilla Pillay, Wynne Chua, Eide Sterling, Swee Tian Quek, Malini Olivo
No abstract text is available yet for this article.
August 16, 2018: Clinical Breast Cancer
Barbara Pistilli, Chafika Mazouni, Anna Zingarello, Matthieu Faron, Mahasti Saghatchian, Michael Grynberg, Marc Spielmann, Paul Kerbrat, Henri Roché, Veronique Lorgis, Thomas Bachelot, Mario Campone, Christelle Levy, Anthony Gonçalves, Anne Lesur, Corinne Veyret, Laurence Vanlemmens, Jerome Lemonnier, Suzette Delaloge
BACKGROUND: The likelihood of menses recovery varies greatly in premenopausal patients receiving adjuvant chemotherapy for breast cancer. Quantifying this probability for each patient could better inform the chemotherapy discussion and individualize fertility counseling. We performed a pooled analysis of the PACS04 and PACS05 adjuvant randomized trials to develop a nomogram to estimate the probability of menses recovery at 3, 6, and 18 months after the end of adjuvant chemotherapy. PATIENTS AND METHODS: Women who were premenopausal and aged ≤ 50 years at randomization in the PACS04 and PACS05 trials were included in the present analysis...
August 23, 2018: Clinical Breast Cancer
Won Kyung Cho, Won Park, Doo Ho Choi, Yong Bae Kim, Jin Ho Kim, Su Ssan Kim, Kyubo Kim, Jin Hee Kim, Sung Ja Ahn, Sun Young Lee, Jeongshim Lee, Sang-Won Kim, Jeanny Kwon, Ki Jung Ahn
BACKGROUND: Given the lack of established indications for elective nodal irradiation (ENI) in ypN0 patients after neoadjuvant chemotherapy (NAC) and breast-conserving surgery (BCS), we set out to investigate the role of ENI in ypN0 patients according to subtype and pathologic complete remission (pCR) status. PATIENTS AND METHODS: We analyzed 261 patients who received NAC followed by BCS and adjuvant radiotherapy in 13 institutions of the Korean Radiation Oncology Group from 2005 to 2011...
August 28, 2018: Clinical Breast Cancer
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"